Thursday, March 30, 2023
My-StockMarket
No Result
View All Result
  • Markets
  • Reviews
  • Cryptocurrency
  • Contacts
SUBSCRIBE
  • Markets
  • Reviews
  • Cryptocurrency
  • Contacts
No Result
View All Result
My-StockMarket
No Result
View All Result

Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

by Armando Henderson
January 25, 2022
in Markets
0

Onconova Therapeutics (NASDAQ: ONTX) was reduced by Zacks Investment Research  from a “get” score to a “hold” ranking in a research note issued to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on discovering and also establishing small particle medicine candidates to deal with cancer. The Business‘s products under different stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts likewise lately talked about the firm. Noble Financial reissued a “get” ranking and issued a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average cost of $2.90 as well as a two-hundred day relocating typical price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as a negative web margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the agreement price quote of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A variety of hedge funds have recently bought and sold shares of ONTX. GSA Resources Partners LLP got a brand-new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Monitoring LP acquired a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and development of oncology therapeutics. It focuses on uncovering and developing little molecule medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more regarding research offerings from Zacks Investment Research, check out Zacks.com.

This instant news alert was generated by narrative scientific research technology and financial data from Market in order to supply viewers with the fastest and most accurate coverage. This story was evaluated by Market’s editorial team before magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market keeps an eye on Wall Street’s premier and also finest doing research experts as well as the stocks they advise to their customers every day. Market has actually recognized the five stocks that cover experts are quietly murmuring to their clients to get now prior to the broader market catches on … as well as Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” score among analysts, premier experts think these five stocks are much better buys.

Related Posts

louis vuitton 5th Ave, Midtown, NYC | MY STOCKMARKET
Markets

Making Smart Investments: The Pros and Cons of Investing in Luxury Goods Stocks

March 1, 2023
The Benefits of UPS Store: What You Need to Know
Markets

The Benefits of UPS Store: What You Need to Know

January 20, 2023
Fed Chair Powell | My-StockMarket
Markets

Fed Chair Powell claims smaller sized rates of interest walkings might start in December

December 4, 2022
Dow rises to start the week as investors wait for midterm elections and rising cost of living report
Markets

Dow rises to start the week as investors wait for midterm elections and rising cost of living report

November 7, 2022
Market Chart - My-StockMarket
Markets

Oil stocks see more than 100% rise so far in 2022

October 18, 2022
Is Apple Stock a Buy?
Markets

Is Apple Stock a Buy?

October 12, 2022
Next Post

Best 15 Websites Like KissCartoon To Watch Flicks (KissCartoon Alternatives)

  • About
  • Advertise
  • Privacy & Policy
  • Contact

DISCLAIMER
This demo site is only for demonstration purposes to JNews WordPress theme.
© 2018 JNews. All right go to their respective owners

No Result
View All Result
  • Reviews
  • How To
  • Apps
  • Devices
  • Games

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.